NCT03655977

Brief Summary

The main goal of this project is to evaluate the potential and feasibility of hybrid PET/MRI functional imaging to non-invasively measure tumor characteristics for radiation therapy planning (RT) for cervical cancer. It will be assessed how the complementary information of tumor characteristics can contributed to better understanding of tumor delineation. Another endpoint of this study is to evaluate a new PET-tracer (68Ga-NODAGA- E\[c(RGDyK)\]2) enabling imaging of tumor-angiogenesis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
25

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 2, 2018

Completed
1 month until next milestone

Study Start

First participant enrolled

September 1, 2018

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 4, 2018

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2021

Completed
Last Updated

September 4, 2018

Status Verified

August 1, 2018

Enrollment Period

3 years

First QC Date

August 2, 2018

Last Update Submit

August 30, 2018

Conditions

Keywords

Cervical cancerTreatment planningPET/MRI imaging

Outcome Measures

Primary Outcomes (2)

  • Feasibility of PET/MRI in radiation treatment planning workflow

    Assess the feasibility of PET/MRI in the radiation treatment planning workflow with respect to the adequacy of tumor delineation and planning target volume using PET/MRI data as compared to MRI-only planning.

    1 year

  • Measure of angiogenesis with 68Ga-NODAGA-E[c(RGDyK)]2 radio-tracer in patient with cervical cancer

    Measure of voxel values, metabolic volume represents angiogenesis volume in patients with cervical cancer. Angiogenesis can be analysed qualitatively.

    1 hour

Secondary Outcomes (3)

  • Feasibility of dose planning using MRI

    1 year

  • Changes in PTV between conventional MRI and PET/MRI

    1 month

  • measuring tumor metabolism using Standard Uptake Value (SUV).

    1 hour

Study Arms (1)

Cervical cancer patients

EXPERIMENTAL

This pilot study includes 25 women with histologically proven advanced stage primary cervical cancer (FIGO stages ≥IB2-IVA), planned for treatment with radio-chemotherapy.

Drug: 68Ga-NODAGA-E[c(RGDyK)]2Device: PET/MRI scan instead of only MRI

Interventions

200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 will be administered before external beam radiation therapy (EBRT).

Also known as: RGD-PET
Cervical cancer patients

Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning external beam radiation therapy.

Cervical cancer patients

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosed with cervical cancer stage
  • Tumor \> 1cm
  • Referred for EBRT and BT planning
  • Age \> 18 years
  • Informed consent

You may not qualify if:

  • Prior RT of the pelvic region
  • Pregnancy and lactation
  • Claustrophobia
  • MR-incompatible implants

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Copenhagen

Copenhagen, 2200, Denmark

Location

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Officials

  • Barbara Malene Fisher

    Dept. of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
medical doctor

Study Record Dates

First Submitted

August 2, 2018

First Posted

September 4, 2018

Study Start

September 1, 2018

Primary Completion

September 1, 2021

Study Completion

September 1, 2021

Last Updated

September 4, 2018

Record last verified: 2018-08

Locations